Comparison of Somatostatin Analogue (SA) and Chemotherapy (CT) in Neuroendocrine Tumors (NET) Patients with Ki-67 ≤20%

#1373

Introduction: SA and CT are the most important treatment options for grade (G) 1 and G2 NET patients.

Aim(s): To compare SA and CT with progression-free survival (PFS), and to find patients group who are more effective of these treatments in NETs with Ki-67 index ≤20%.

Materials and methods: Patients who received SA or CT, were unresectabl and metastatic NETs with Ki-67 index ≤ 20%. These patients were selected from 13 centers between 2000-2014. The patients were evaluated retrospectively for factors effecting PFS by the Kaplan-Meire and Cox-Regression methods.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Özaslan E

Authors: Özaslan E, Koca S, Sevinç A, Hacıoğlu B, Özçelik M,

Keywords: Somatostatin analogue, NET, Ki-67,